Nebenwirkungen · Zaltrap
ZALTRAP 25 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15–16
HOS-215799 · Präparat HOS-155534
15 Immunogenicity data are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medicinal products, and underlying disease. For these reasons, comparison of the incidence of antibodies to ZALTRAP with the incidence of antibodies to other products may be misleading.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-29T14:23:00Z · SHA-256 5b4c1b4848635140cdb6155c414b72c6acf77bc314124cac5763c972a8858b1a · Passage a29472922d7ee97029405e7ae11f958c0700e41c1c250108466889ab03f7bd48 · Zeichen 23570–24027 im Abschnitt